Thursday, 25 April 2024
Kalvista Pharmaceuticals Inc.
05:07 | 17/3/18
Market Exclusive
On March 16, 2018, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the three months ended January 31, 2018.
more»
00:26 | 17/3/18
Business Wire
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.
more»
01:22 | 6/3/18
Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will ...
more»
06:03 | 15/2/18
Frisco Fastball
About 10,176 shares traded. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has declined 43.18% since February 14, 2017 and is downtrending.
more»
13:33 | 5/2/18
Aiken Advocate
Currently, Kalvista Pharmaceuticals Inc (KALV) has a 14-day ATR of 0.71. The Average True Range is an investor tool used to measure stock volatility.
more»
02:07 | 3/2/18
Stock Rover
The Return on Invested Capital (aka ROIC) Score for KalVista Pharmaceuticals, Inc. (NasdaqGM:KALV) is . The Return on Invested Capital is a ratio that determines whether a company is profitable or not.
more»
06:03 | 25/1/18
Aiken Advocate
Taking a closer look into the volatility on shares of KalVista Pharmaceuticals, Inc. (:KALV), we notice that the stock is 13.83% off of the 20-Day Simple Moving Average.
more»
15:59 | 24/1/18
Nelson Research
Even though short-term trading can be very profitable, it can also be a huge risk. Short-term lasts from anywhere from a few minutes or several days or weeks.
more»
03:03 | 24/1/18
Post Analyst
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) recovered 122.45% of its value since hitting low of $5.48. The recent move of 8.55% gain helped the stock to close at $12.19 when trading ended on 01/22/2018.
more»
06:15 | 20/1/18
The Ledger Gazette
KalVista Pharmaceuticals logo KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |